Lamivudine/raltegravir

Last updated

Lamivudine/raltegravir
Combination of
Lamivudine Reverse-transcriptase inhibitor
Raltegravir Integrase inhibitor
Clinical data
Trade names Dutrebis
Routes of
administration 		Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. [1] It contains lamivudine and raltegravir. It is taken by mouth. [1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. [1] It was approved for medical use in the United States in 2015. [1] [2]

Lamivudine/raltegravir is not available in the United States. [3]

References

  1. 1 2 3 4 "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 18 January 2017. Retrieved 10 December 2017.
  2. ↑ "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Archived from the original on 15 April 2016. Retrieved 24 January 2020.
  3. ↑ "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.